Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Non-Steroidal Anti-Inflammatory Drugs in Management of Covid-19; a Systematic Review on Current Evidence Publisher Pubmed



Yousefifard M1 ; Zali A2 ; Zarghi A3 ; Madani Neishaboori A1 ; Hosseini M4, 5 ; Safari S6, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Functional Neurosurgery Research Center, Shohada Tajrish Neurosurgical Comprehensive Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Department of Medicinal Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. Pediatric Chronic Kidney Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  7. 7. Emergency Department, Shohadye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: International Journal of Clinical Practice Published:2020


Abstract

Background: Since there is still no definitive conclusion regarding which non-steroidal anti-inflammatory drugs (NSAIDs) are most effective and safe in viral respiratory infections, we decided to evaluate the efficacy and safety of various NSAIDs in viral respiratory infections so that we can reach a conclusion on which NSAID is best choice for coronavirus disease 2019 (COVID-19). Methods: A search was performed in Medline (via PubMed), Embase and CENTRAL databases until 23 March 2020. Clinical trials on application of NSAIDs in viral respiratory infections were included. Results: Six clinical trials were included. No clinical trial has been performed on COVID-19, Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome infections. Studies show that ibuprofen and naproxen not only have positive effects in controlling cold symptoms, but also do not cause serious side effects in rhinovirus infections. In addition, it was found that clarithromycin, naproxen and oseltamivir combination leads to decrease in mortality rate and duration of hospitalisation in patients with pneumonia caused by influenza. Conclusion: Although based on existing evidence, NSAIDs have been effective in treating respiratory infections caused by influenza and rhinovirus, since there is no clinical trial on COVID-19 and case-reports and clinical experiences are indicative of elongation of treatment duration and exacerbation of the clinical course of patients with COVID-19, it is recommended to use substitutes such as acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs in management of COVID-19 patients until there are enough evidence. Naproxen may be a good choice for future clinical trials. © 2020 John Wiley & Sons Ltd
Other Related Docs
12. Nsaids and Covid-19: A New Challenging Area, Pharmaceutical Sciences (2020)
13. Covid-19: Features, Clinical Course and Concerns, Journal of Cellular and Molecular Anesthesia (2020)
26. Covid-19: A New Horizon in Congenital Heart Diseases, Frontiers in Pediatrics (2021)
27. Immune-Based Therapy for Covid-19, Advances in Experimental Medicine and Biology (2021)
35. A Review on Currently Available Potential Therapeutic Options for Covid-19, International Journal of General Medicine (2020)
37. Cancer Care Management During the Covid-19 Pandemic, Risk Management and Healthcare Policy (2020)
40. Cardiovascular Manifestations in Covid-19 Patients: A Systematic Review and Meta-Analysis, Journal of Cardiovascular and Thoracic Research (2021)
43. Clinical Manifestations of Covid-19, Advances in Experimental Medicine and Biology (2021)
44. Being a Front-Line Dentist During the Covid-19 Pandemic: A Literature Review, Maxillofacial Plastic and Reconstructive Surgery (2020)